Aktienanalyse zu OPKO Health Inc (OPK)OPKOPKO Health Inc

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

OPKO Health Inc is currently trading at $1.48 with a recent RSI of 61.38, indicating it is in a neutral range but not yet overbought. The company has shown a 4.3% year-over-year revenue increase to $163.5 million in Q2, but it provided a softer guidance for Q3, forecasting revenues between $131 million and $142 million. The main risk is the downgrade by Barrington, which suggests that profitability in 2026 is 'highly unlikely' and the upper end of the FY26 guidance is 'seriously aspirational.'

6 analysts cover OPK: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 2.75.